20 articles
Comprehensive review reveals therapeutic plasma exchange may improve survival and organ function in sepsis patients through multiple mechanisms.
Comprehensive review explores plasmapheresis techniques for removing harmful blood components and potential therapeutic benefits.
Comprehensive review reveals TPE could shift from reactive treatment to preventative therapy for cardiovascular, metabolic, and neurological aging.
Randomized trial finds therapeutic plasma exchange improves lab values but doesn't reduce 30-day mortality in acute liver failure patients.
Meta-analysis of 5,336 patients shows therapeutic plasma exchange significantly improves survival in acute-on-chronic liver failure.
Multi-center study reveals therapeutic plasma exchange may improve survival in severe amatoxin poisoning cases.
A 2025 JAMA review breaks down how plasma exchange, rituximab, and caplacizumab transformed survival in this rare blood-clotting emergency.
First controlled study shows therapeutic plasma exchange safely reduces biological age markers across multiple molecular pathways.
Therapeutic plasma exchange successfully reduced soluble mesothelin levels by 44%, potentially restoring cancer drug effectiveness.
A first-of-its-kind trial shows therapeutic plasma exchange plus IVIG reduced biological age by an average of 2.6 years, confirmed by multi-omics analysis.
Therapeutic plasma exchange emerges as potential treatment for severe postural tachycardia syndrome with autoimmune features.
Une méta-analyse portant sur 475 crises révèle que les échanges plasmatiques thérapeutiques offrent des taux de réponse élevés dans le MOGAD, une maladie cérébrale auto-immune rare.
Lymphoplasmapheresis reduces ICU time and ventilator dependence compared to standard plasma exchange in severe myasthenia gravis episodes.
Updated guidelines for anti-GBM disease show how plasma exchange plus immunosuppression dramatically improves survival rates.
Biohacker Ben Greenfield shares his three-day regenerative therapy journey including young plasma replacement and multiple longevity protocols.
Review reveals critical differences between congenital and immune-mediated thrombotic thrombocytopenic purpura in children.
The 2025 ISTH guideline update elevates recombinant ADAMTS-13 as the preferred therapy for congenital TTP while maintaining prior immune TTP recommendations.
Un essai de phase 2 randomisé montre que le CM313 atteint un taux de réponse de 83 % contre 20 % sous placebo dans le purpura thrombocytopénique immunologique réfractaire au traitement.
Biohacker Ben Greenfield undergoes plasma exchange with young donor blood plus five other cutting-edge longevity treatments.
Scientists explore how transferring plasma from young donors could rejuvenate aging tissues and extend healthspan.
